CKD changes how the body processes most medications — reduced eGFR slows drug clearance, raises toxicity risk, and alters electrolyte responses. The most critical interactions in CKD: Metformin is absolutely contraindicated at eGFR below 30; NSAIDs worsen kidney function at every stage; and combining NSAIDs + ACE inhibitors + diuretics creates the "Triple Whammy" — a recipe for acute kidney injury (AKI).
| Drug / Class | G1–G2 (eGFR ≥60) | G3a–G3b (30–59) | G4 (15–29) | G5 / Dialysis (<15) |
|---|---|---|---|---|
| Metformin | Full dose | G3a: reduce; G3b: max 1000 mg/day | CONTRAINDICATED | CONTRAINDICATED |
| ACEi / ARBs (RAASi) | Initiate; renoprotective | Continue; monitor K+ and creatinine | Continue unless K+ >5.5 | Continue with caution; monitor closely |
| SGLT2i (Dapagliflozin, Empagliflozin) | First-line in CKD + T2DM | Continue; cardiorenal benefit | Initiate down to eGFR 20 | Continue (GFR effect lost but cardio benefit persists) |
| Finerenone (Kerendia) | Start if UACR >30 + T2DM + K+ ≤5.0 | Continue; monitor K+ | Continue if eGFR ≥25 + K+ ≤5.0 | Insufficient data; specialist decision |
| NSAIDs (Ibuprofen, Naproxen) | Use minimum dose; short term only | AVOID — acutely worsens GFR | CONTRAINDICATED | CONTRAINDICATED |
| Statins | Use; cardiovascular benefit | Continue; reduce dose for rosuvastatin at low eGFR | Continue; generally safe | Avoid new initiation at G5 dialysis (AURORA trial) |
| Paracetamol / Acetaminophen | Safe at recommended doses | Preferred analgesic in CKD | Safe; first-choice pain relief | Safe; preferred over NSAIDs |
Metformin remains the first-line oral antidiabetic drug and should not be withdrawn prematurely from CKD patients. The concern is Metformin-Associated Lactic Acidosis (MALA) — a rare but potentially fatal complication that occurs when Metformin accumulates due to impaired renal clearance.
ACE inhibitors (lisinopril, ramipril, enalapril) and ARBs (losartan, valsartan, irbesartan) are the cornerstone of CKD renoprotection — they reduce intraglomerular pressure and proteinuria, slowing kidney disease progression. A common mistake is to discontinue RAASi when eGFR drops or potassium rises slightly.
SGLT2 inhibitors (dapagliflozin/Farxiga and empagliflozin/Jardiance) reduce CKD progression through multiple mechanisms: natriuresis, reduced intraglomerular pressure, anti-inflammatory effects, and cardioprotection. The 2020 DAPA-CKD trial demonstrated benefit even in non-diabetic CKD patients.
| Landmark Trial | Drug | Key Finding | Population |
|---|---|---|---|
| DAPA-CKD (NEJM 2020) | Dapagliflozin 10 mg | 39% reduction in CKD progression; 31% lower mortality | CKD G2–G4 + T2DM or non-DM + UACR >200 |
| EMPA-KIDNEY (NEJM 2023) | Empagliflozin 10 mg | 28% reduction in kidney disease progression | CKD G2–G4 with eGFR 20–45 or UACR ≥200 |
| CREDENCE (NEJM 2019) | Canagliflozin 100 mg | 34% reduction in CKD progression | CKD + T2DM + UACR 300–5000 |
SGLT2 inhibitors must be temporarily held during situations that increase risk of euglycemic DKA:
Resume when eating normally and clinically stable.
Finerenone is a selective non-steroidal mineralocorticoid receptor antagonist (MRA) — different from spironolactone (steroidal) because it has higher selectivity and lower off-target hormonal side effects. Per KDIGO 2024, it is indicated for CKD + T2DM patients to reduce inflammation, fibrosis, and proteinuria on top of RAASi and SGLT2i.
The Triple Whammy combination reduces glomerular filtration to near-zero by eliminating both afferent dilation and efferent resistance simultaneously:
This combination causes acute tubular necrosis and oliguric AKI. Patients on RAASi and diuretics must avoid all NSAIDs — including over-the-counter ibuprofen. Recommend paracetamol as the safe alternative.
Can you take Metformin with CKD?
Yes, with restrictions. eGFR ≥45: full dose. eGFR 30–44: maximum 1,000 mg/day. eGFR <30: absolutely contraindicated — risk of fatal MALA. Always hold during acute illness or iodinated contrast procedures.
What is the Triple Whammy in CKD?
NSAID + ACE inhibitor or ARB + diuretic. This combination eliminates glomerular filtration pressure, causing acute kidney injury. Patients on RAASi and diuretics must never take NSAIDs — even OTC ibuprofen. Use paracetamol instead.
Are SGLT2 inhibitors safe in advanced CKD?
Yes — KDIGO 2024 endorses SGLT2 inhibitors (dapagliflozin, empagliflozin) for initiation down to eGFR 20 and continuation until dialysis. Apply Sick Day Protocol: hold during acute illness, vomiting, or surgery to prevent euglycemic DKA.
When should ACE inhibitors be stopped in CKD?
RAASi should NOT be stopped based on stage alone. Hold only if: K+ persistently >5.5 mEq/L despite binders, creatinine rises >30% within 4 weeks (suspect renal artery stenosis), or during pregnancy (absolute contraindication). Resume once potassium is corrected.